Trial Profile

A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Anti CEA CAR T cell therapy-Chongqing Precision Biotech (Primary) ; Cyclophosphamide; Fludarabine
Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions
Sponsors Chongqing Precision Biotech Co., Ltd

Most Recent Events

12 Nov 2023 Planned End Date changed from 15 Sep 2024 to 15 Sep 2025.
12 Nov 2023 Planned primary completion date changed from 15 Sep 2023 to 15 Sep 2024.
15 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com